Skip to Content
Merck
CN
All Photos(1)

Documents

1604610

USP

Risedronate sodium

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

Risedronic acid monosodium salt hemi(pentahydrate)

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H10NNaO7P2 · 2.5H2O
CAS Number:
329003-65-8
Molecular Weight:
350.13
MDL number:
MFCD01706268
UNSPSC Code:
41116107
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

risedronate

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

OP(C(P(O)([O-])=O)(O)CC1=CC=CN=C1)(O)=O.[Na+]

InChI

1S/2C7H11NO7P2.2Na.5H2O/c2*9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;;;;;;;/h2*1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);;;5*1H2/q;;2*+1;;;;;/p-2

InChI key

HYFDYHPNTXOPPO-UHFFFAOYSA-L

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Risedronate sodium is a member of the pyridinyl class of bisphosphonates. It is mostly used as an antiresorptive agent. It can be used in treating and preventing postmenopausal and glucocorticoid-induced osteoporosis.

Application

Risedronate sodium USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Risedronate Sodium Tablets
  • Risedronate Sodium Delayed-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1604621

Risedronate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1604632

Risedronate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1604643

Risedronate Related Compound C, United States Pharmacopeia (USP) Reference Standard

Y0001558

Risedronate impurity A, European Pharmacopoeia (EP) Reference Standard

Y0001540

Risedronate impurity E, European Pharmacopoeia (EP) Reference Standard

Y0001541

Risedronate sodium 2.5-hydrate, European Pharmacopoeia (EP) Reference Standard

PHR2079

Risedronate Impurity D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2078

Risedronate Impurity C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2075

Risedronate Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2077

Risedronate Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazardExclamation mark
GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H319,H361,H371

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Repr. 2 - STOT SE 2

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

CUNHA F.
American Journal of Surgery, 76(3), 244-260 (1948)
Eliska Vaculikova et al.
Molecules (Basel, Switzerland), 19(11), 17848-17861 (2014-11-07)
One approach for the enhancement of oral drug bioavailability is the technique of nanoparticle preparation. Risedronate sodium (Biopharmaceutical Classification System Class III) was chosen as a model compound with high water solubility and low intestinal permeability. Eighteen samples of risedronate
Yoshihisa Hirota et al.
PloS one, 10(4), e0125737-e0125737 (2015-04-16)
UbiA prenyltransferase domain-containing protein 1 (UBIAD1) plays a significant role in vitamin K2 (MK-4) synthesis. We investigated the enzymological properties of UBIAD1 using microsomal fractions from Sf9 cells expressing UBIAD1 by analysing MK-4 biosynthetic activity. With regard to UBIAD1 enzyme
Jin Woo Park et al.
Archives of pharmacal research, 37(12), 1560-1569 (2013-11-21)
Risedronate is widely used clinically to treat osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and multiple myeloma. However, its oral efficacy is restricted due to its low bioavailability and severe gastrointestinal adverse effects. This study was designed to evaluate the effect

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service